ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
125.288,38
1,57%
S&P 500
5.762,62
0,42%
US Dollar vs BRL
5,793
0,49%
Bitcoin
88.433,96
-1,67%
Brent Oil
70,325
1,42%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Assembly Biosciences Inc (ASMB)

  7. Assembly Biosciences Inc (ASMB) Notícias

ASMB

Assembly Biosciences (ASMB)

Assembly Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ASMB
DataHoraFonteTítuloCódigoCompanhia
26/02/202510:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta VirusNASDAQ:ASMBAssembly Biosciences Inc
20/02/202518:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ASMBAssembly Biosciences Inc
20/02/202510:00GlobeNewswire Inc.Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital HerpesNASDAQ:ASMBAssembly Biosciences Inc
14/02/202518:58Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASMBAssembly Biosciences Inc
31/12/202418:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
26/12/202410:00GlobeNewswire Inc.Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis BNASDAQ:ASMBAssembly Biosciences Inc
23/12/202413:59Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ASMBAssembly Biosciences Inc
19/12/202410:00GlobeNewswire Inc.Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development ProgramsNASDAQ:ASMBAssembly Biosciences Inc
14/11/202417:22Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ASMBAssembly Biosciences Inc
07/11/202418:42Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASMBAssembly Biosciences Inc
07/11/202418:24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ASMBAssembly Biosciences Inc
07/11/202418:05GlobeNewswire Inc.Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
23/09/202409:00GlobeNewswire Inc.Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366NASDAQ:ASMBAssembly Biosciences Inc
08/08/202417:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ASMBAssembly Biosciences Inc
08/08/202417:05GlobeNewswire Inc.Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent UpdatesNASDAQ:ASMBAssembly Biosciences Inc
15/07/202409:00GlobeNewswire Inc.Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus WorkshopNASDAQ:ASMBAssembly Biosciences Inc
18/06/202409:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus InfectionNASDAQ:ASMBAssembly Biosciences Inc
17/06/202409:00GlobeNewswire Inc.Assembly Biosciences Announces $12.6 Million in Equity FinancingsNASDAQ:ASMBAssembly Biosciences Inc
10/06/202409:00GlobeNewswire Inc.Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366NASDAQ:ASMBAssembly Biosciences Inc
05/06/202409:00GlobeNewswire Inc.Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024NASDAQ:ASMBAssembly Biosciences Inc
22/05/202409:00GlobeNewswire Inc.Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024NASDAQ:ASMBAssembly Biosciences Inc
08/05/202417:05GlobeNewswire Inc.Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
28/03/202417:05GlobeNewswire Inc.Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent HighlightsNASDAQ:ASMBAssembly Biosciences Inc
08/02/202410:00GlobeNewswire Inc.Assembly Biosciences Announces Effective Date of Reverse Stock SplitNASDAQ:ASMBAssembly Biosciences Inc
04/01/202410:00GlobeNewswire Inc.Assembly Biosciences Provides Anticipated Development Milestones for 2024NASDAQ:ASMBAssembly Biosciences Inc
21/12/202318:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ASMBAssembly Biosciences Inc
21/12/202318:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202318:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ASMBAssembly Biosciences Inc
11/12/202318:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ASMBAssembly Biosciences Inc
22/11/202318:12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ASMBAssembly Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ASMB

Seu Histórico Recente

BIT
S28915
Societe Generale Effekten
BIT
S29110
Societe Generale Effekten
BIT
F24510
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios